Verinome Scientific Methods & Platform Boundaries
A transparent technical disclosure of our evidence grading rubric, provider compatibility matrix, genomic data flow, and clinical limitations.
The A–D Evidence Grading Rubric
Every genotype-specific finding in Verinome is mapped to a deterministic evidence grade based on clinical consensus, guideline strength, and replication rigor.
Backed by official clinical consensus guidelines from CPIC (Clinical Pharmacogenetics Implementation Consortium Level 1A/1B) or ACMG (American College of Medical Genetics). Findings have direct pharmacogenomic implications or definitive risk associations replicated across multiple high-powered cohorts.
Supported by multiple independent, peer-reviewed cohort replications or well-characterized enzymatic mechanisms (e.g. CYP1A2 caffeine clearance, ALDH2 acetaldehyde kinetics). Clear statistical significance with moderate effect size.
Derived from single genome-wide association studies (GWAS) or preliminary observational research. Modest odds ratios; subject to environmental confounders and population-specific portability decay.
Widespread popular biohacking claims or candidate gene studies with conflicting replication records (e.g. certain COMT dopamine personality extrapolations). Labeled transparently to prevent consumer deception.
Supported Consumer DNA Formats
Verinome's zero-dependency in-browser parser is tested against raw exports from major direct-to-consumer genotyping providers:
| Provider & Chip Version | Format Structure | Reference Build | Compatibility Status |
|---|---|---|---|
| 23andMe (v3, v4, v5) | 4-Column TSV (rsid, chr, pos, genotype) | GRCh37 | ✓ Fully Supported (Tested) |
| AncestryDNA (v1, v2) | 5-Column TSV (rsid, chr, pos, allele1, allele2) | GRCh37 | ✓ Fully Supported (Tested) |
| MyHeritage DNA | Quoted CSV (RSID, CHROMOSOME, POSITION, RESULT) | GRCh37 | ✓ Fully Supported (Tested) |
| FamilyTreeDNA (FTDNA) | Quoted CSV (RSID, CHROMOSOME, POSITION, RESULT) | GRCh37 | ✓ Fully Supported (Tested) |
| Generic TSV / CSV | Tab or Comma Delimited with standard rsID headers | GRCh37 / GRCh38 | ✓ Supported with Fallback |
Genomics Correctness & Array Limitations
Direct-to-consumer DNA tests rely on hybridisation microarrays targeting ~650,000 discrete positions. It is essential to understand what consumer array data can and cannot reveal:
- Microarray Limitation: Consumer arrays read approximately 0.02% of human single-nucleotide variants. They do not perform whole-genome sequencing (WGS).
- No Phasing or Copy Number Variations (CNVs): Single-SNP microarrays cannot determine chromosomal phasing (which allele came from which parent) or gene duplications/deletions (e.g. CYP2D6 *5 deletion or *1xN gene duplication).
- Complex Indels Are Catalog-Only: Complex frameshift deletions (such as BRCA1 185delAG) cannot be called reliably on consumer arrays. Absence from your file does not prove absence in your body.
- Not a Medical Diagnostic Device: Verinome reports are educational and evidence-graded. Any pharmacogenomic finding or carrier status requires diagnostic clinical confirmation (e.g. Sanger sequencing or targeted qPCR) ordered by a qualified physician.
Now you know exactly what it can and can’t do.
Run it on your own file and see every result graded, free to try, on your device, in under a second.
Free preview first · 30-day refund if it did not work or was not as described.